UniProt Q5TCY1 · PDB · AlphaFold · Substrate: MBP · Clone: Catalytic domain (aa1-479)
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Capivasertib | 27.7% | 72.3% | 96.48 | 0.644 |
| 2 | Vemurafenib | 20.4% | 79.6% | 96.49 | 0.598 |
| 3 | Umbralisib | 19.0% | 81.0% | 98.74 | 0.670 |
| 4 | Ibrutinib | 17.4% | 82.6% | 94.74 | 0.723 |
| 5 | Cabozantinib | 16.8% | 83.2% | 92.73 | 0.751 |
| 6 | Temsirolimus | 15.9% | 84.1% | 100.00 | 0.740 |
| 7 | Lapatinib | 15.5% | 84.5% | 99.25 | 0.616 |
| 8 | Regorafenib | 15.1% | 84.9% | 95.99 | 0.719 |
| 9 | Sirolimus | 14.2% | 85.8% | 100.00 | 0.708 |
| 10 | Fostamatinib | 14.0% | 86.0% | 96.74 | 0.613 |
| 11 | Trametinib | 14.0% | 86.0% | 99.50 | 0.718 |
| 12 | Infigratinib | 13.7% | 86.3% | 98.24 | 0.710 |
| 13 | Paxalisib | 13.3% | 86.7% | 99.75 | 0.609 |
| 14 | Apatinib | 12.9% | 87.1% | 97.73 | 0.704 |
| 15 | Abemaciclib | 12.7% | 87.3% | 91.48 | 0.563 |
| 16 | Dasatinib | 12.1% | 87.9% | 87.97 | 0.699 |
| 17 | Gefitinib | 11.6% | 88.4% | 99.25 | 0.650 |
| 18 | Cobimetinib | 11.6% | 88.4% | 100.00 | 0.644 |
| 19 | Bosutinib | 11.2% | 88.8% | 87.22 | 0.555 |
| 20 | Everolimus | 11.0% | 89.0% | 100.00 | 0.706 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.07
- Epithelial log2(TPM+1): 0.37
- Fold change: -0.30
- Status: No significant change
Selectivity landscape vs inhibition on TTBK1
Each point is one of the 92 approved drugs; color = inhibition % on TTBK1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…